Approved Research
Concurrent Challenges: Prognosis of Pulmonary Hypertension in Lung Cancer Patients
Lay summary
Aims and Scientific Rationale:
Our research aims to explore a crucial health issue: the impact of pulmonary hypertension (PH) on patients with lung cancer. Lung cancer is a leading cause of cancer death worldwide, and its prognosis is often worsened when combined with PH, a condition characterized by high blood pressure in the lungs. This study seeks to understand how PH affects lung cancer outcomes, the role of PH severity in lung cancer treatment, and to identify any common characteristics and genetic markers in lung cancer patients who develop PH. Our goal is to improve treatment and management strategies for these patients.
Project Duration:
From Jan 2024 to Dec 2029
Public Health Impact:
This research holds significant public health importance. By understanding the interplay between lung cancer and PH, we can develop better screening methods, leading to earlier diagnosis and potentially more effective treatment options. Additionally, by identifying genetic markers associated with worse outcomes in lung cancer patients with PH, we can move towards more personalized medicine. This means treatments can be tailored to individual patients based on their genetic makeup, improving the effectiveness of the treatment and potentially reducing side effects.
Our findings could also guide healthcare providers in making informed decisions about managing lung cancer patients who also suffer from PH. This is crucial, as managing one condition without considering the other could lead to less effective treatment and poorer patient outcomes. Furthermore, our research might influence health policy and education, ensuring resources are allocated efficiently and healthcare professionals are well-informed about this complex medical issue.
In summary, this study not only aims to fill a gap in current medical research but also has the potential to significantly improve the lives of lung cancer patients with PH. It could lead to advancements in treatment, better patient care, and ultimately, contribute to reducing the burden of lung cancer and PH on patients and healthcare systems worldwide.